Riluzole, a drug that has been used for more than 20 years to slow the progression of ALS, commonly known as Lou Gehrig’s disease, was shown in a pilot phase 2 study to slow brain metabolic decline and have a positive effect on cognitive performance versus placebo in people with mild Alzheimer’s disease.